348 related articles for article (PubMed ID: 23886825)
1. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
Ringelstein M; Harmel J; Distelmaier F; Ingwersen J; Menge T; Hellwig K; Kieseier B; Mayatepek E; Hartung HP; Kuempfel T; Aktas O
Mult Scler; 2013 Oct; 19(11):1544-7. PubMed ID: 23886825
[TBL] [Abstract][Full Text] [Related]
2. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.
Nakashima I; Takahashi T; Cree BA; Kim HJ; Suzuki C; Genain CP; Vincent T; Fujihara K; Itoyama Y; Bar-Or A
J Clin Neurosci; 2011 Jul; 18(7):997-8. PubMed ID: 21565508
[TBL] [Abstract][Full Text] [Related]
3. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
[TBL] [Abstract][Full Text] [Related]
5. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
[TBL] [Abstract][Full Text] [Related]
6. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
[TBL] [Abstract][Full Text] [Related]
7. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
Palace J; Leite MI; Nairne A; Vincent A
Arch Neurol; 2010 Aug; 67(8):1016-7. PubMed ID: 20697055
[TBL] [Abstract][Full Text] [Related]
8. [Neuromyelitis optica in children. Two case reports].
Tosello B; Halbert C; Mancini J; Chabrol B; Boucraut J; Milh M
Arch Pediatr; 2012 Aug; 19(8):827-31. PubMed ID: 22789744
[TBL] [Abstract][Full Text] [Related]
9. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
[TBL] [Abstract][Full Text] [Related]
10. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
11. A review of cases of neuromyelitis optica.
Bomprezzi R; Postevka E; Campagnolo D; Vollmer TL
Neurologist; 2011 Mar; 17(2):98-104. PubMed ID: 21364364
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Gredler V; Mader S; Schanda K; Hegen H; Di Pauli F; Kuenz B; Deisenhammer F; Berger T; Reindl M; Lutterotti A
J Neurol Sci; 2013 May; 328(1-2):77-82. PubMed ID: 23522498
[TBL] [Abstract][Full Text] [Related]
13. B-cell-directed therapy: which B cells should be targeted and how?
Yamamura T; Miyake S
Immunotherapy; 2012 May; 4(5):455-7. PubMed ID: 22642324
[No Abstract] [Full Text] [Related]
14. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder.
Shimizu Y; Fujihara K; Ohashi T; Nakashima I; Yokoyama K; Ikeguch R; Takahashi T; Misu T; Shimizu S; Aoki M; Kitagawa K
Mult Scler; 2016 Oct; 22(11):1413-1420. PubMed ID: 25921053
[TBL] [Abstract][Full Text] [Related]
16. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4.
Kim W; Lee JE; Li XF; Kim SH; Han BG; Lee BI; Kim JK; Choi K; Kim HJ
Mult Scler; 2012 May; 18(5):578-86. PubMed ID: 21965418
[TBL] [Abstract][Full Text] [Related]
17. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica.
Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
[TBL] [Abstract][Full Text] [Related]
19. [Neuromyelitis optica].
Kvistad SA; Wergeland S; Torkildsen Ø; Myhr KM; Vedeler CA
Tidsskr Nor Laegeforen; 2013 Oct; 133(19):2057-61. PubMed ID: 24129537
[TBL] [Abstract][Full Text] [Related]
20. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Shiga Y; Kanaoka C; Fujimori J; Sato S; Itoyama Y
Brain; 2007 May; 130(Pt 5):1235-43. PubMed ID: 17449477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
